The proteoglycan biglycan enhances antigen-specific T cell activation potentially via MyD88 and TRIF pathways and triggers autoimmune perimyocarditis

Journal of Immunology

Volumn 187, Issue 12, 2011, Pages 6217-6226

  Popovic, Zoran V ^a   Wang, Shijun ^a   Papatriantafyllou, Maria ^a   Kaya, Ziya ^b   Porubsky, Stefan ^a   Meisner, Maria ^a   Bonrouhi, Mahnaz ^a   Burgdorf, Sven ^c   Young, Marian F ^d   Schaefer, Liliana ^e   Gröne, Hermann Josef ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^e GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIGLYCAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOID DIFFERENTIATION FACTOR 88; OVALBUMIN; PROTEOGLYCAN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE PERIMYOCARDITIS; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DISEASE COURSE; DISEASE SEVERITY; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN DEPLETION; T LYMPHOCYTE ACTIVATION; WILD TYPE;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; BIGLYCAN; CELLS, CULTURED; COCULTURE TECHNIQUES; CROSS-PRIMING; EPITOPES, T-LYMPHOCYTE; HEK293 CELLS; HUMANS; LIGANDS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MYELOID DIFFERENTIATION FACTOR 88; MYOCARDITIS; NIH 3T3 CELLS; OVALBUMIN; PERICARDITIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; UP-REGULATION;

EID: 83755173455     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003478     Document Type: Article

References (94)

1. Bianco, P., L. W. Fisher, M. F. Young, J. D. Termine, and P. G. Robey. 1990. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J. Histochem. Cytochem. 38: 1549-1563. (Pubitemid 20346965)
2. Dreher, K. L., V. Asundi, D. Matzura, and K. Cowan. 1990. Vascular smooth muscle biglycan represents a highly conserved proteoglycan within the arterial wall. Eur. J. Cell Biol. 53: 296-304.
3. McBride, O. W., L. W. Fisher, and M. F. Young. 1990. Localization of PGI (biglycan, BGN) and PGII (decorin, DCN, PG-40) genes on human chromosomes Xq13-qter and 12q, respectively. Genomics 6: 219-225. (Pubitemid 20164189)
4. Neame, P. J., H. U. Choi, and L. C. Rosenberg. 1989. The primary structure of the core protein of the small, leucine-rich proteoglycan (PG I) from bovine articular cartilage. J. Biol. Chem. 264: 8653-8661. (Pubitemid 19151582)
5. Iozzo, R. V. 1999. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J. Biol. Chem. 274: 18843-18846. (Pubitemid 29314072)
6. Wegrowski, Y., J. Pillarisetti, K. G. Danielson, S. Suzuki, and R. V. Iozzo. 1995. The murine biglycan: complete cDNA cloning, genomic organization, promoter function, and expression. Genomics 30: 8-17.
7. Schaefer, L., K. Macakova, I. Raslik, M. Micegova, H. J. Gröne, E. Schönherr, H. Robenek, F. G. Echtermeyer, S. Grässel, P. Bruckner, et al. 2002. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am. J. Pathol. 160: 1181-1191. (Pubitemid 34224603)
8. Zanotti, S., T. Negri, C. Cappelletti, P. Bernasconi, E. Canioni, C. Di Blasi, E. Pegoraro, C. Angelini, P. Ciscato, A. Prelle, et al. 2005. Decorin and biglycan expression is differentially altered in several muscular dystrophies. Brain 128: 2546-2555. (Pubitemid 41552940)
9. Merline, R., S. Lazaroski, A. Babelova, W. Tsalastra-Greul, J. Pfeilschifter, K. D. Schluter, A. Gunther, R. V. Iozzo, R. M. Schaefer, and L. Schaefer. 2009. Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J. Physiol. Pharmacol. 60(Suppl. 4): 5-13.
10. Schaefer, L., and R. V. Iozzo. 2008. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J. Biol. Chem. 283: 21305-21309.
11. Bereczki, E., and M. Sántha. 2008. The role of biglycan in the heart. Connect. Tissue Res. 49: 129-132.
12. Hardingham, T. E., and A. J. Fosang. 1992. Proteoglycans: many forms and many functions. FASEB J. 6: 861-870.
13. Stanescu, V. 1990. The small proteoglycans of cartilage matrix. Semin. Arthritis Rheum. 20(3, Suppl. 1)51-64.
14. Sjöberg, A. P., G. A. Manderson, M. Mörgelin, A. J. Day, D. Heinegård, and A. M. Blom. 2009. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol. Immunol. 46: 830-839.
15. Stokes, M. B., S. Holler, Y. Cui, K. L. Hudkins, F. Eitner, A. Fogo, and C. E. Alpers. 2000. Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney Int. 57: 487-498. (Pubitemid 30430640)
16. Shimizu-Hirota, R., H. Sasamura, M. Kuroda, E. Kobayashi, M. Hayashi, and T. Saruta. 2004. Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ. Res. 94: 1067-1074. (Pubitemid 38579701)
17. Schaefer, L., H. J. Gröne, I. Raslik, H. Robenek, J. Ugorcakova, S. Budny, R. M. Schaefer, and H. Kresse. 2000. Small proteoglycans of normal adult human kidney: distinct expression patterns of decorin, biglycan, fibromodulin, and lumican. Kidney Int. 58: 1557-1568.
18. O'Brien, K. D., K. L. Olin, C. E. Alpers, W. Chiu, M. Ferguson, K. Hudkins, T. N. Wight, and A. Chait. 1998. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 98: 519-527. (Pubitemid 28371249)
19. Wallace, J. M., R. M. Rajachar, X. D. Chen, S. Shi, M. R. Allen, S. A. Bloomfield, C. M. Les, P. G. Robey, M. F. Young, and D. H. Kohn. 2006. The mechanical phenotype of biglycan-deficient mice is bone- and gender-specific. Bone 39: 106-116. (Pubitemid 43842025)
20. Wallace, J. M., K. Golcuk, M. D. Morris, and D. H. Kohn. 2009. Inbred strain-specific response to biglycan deficiency in the cortical bone of C57BL6/129 and C3H/He mice. J. Bone Miner. Res. 24: 1002-1012.
21. Roberts, H. C., R. Moseley, A. J. Sloan, S. J. Youde, and R. J. Waddington. 2008. Lipopolysaccharide alters decorin and biglycan synthesis in rat alveolar bone osteoblasts: consequences for bone repair during periodontal disease. Eur. J. Oral Sci. 116: 207-216.
22. Kamiya, N., K. Shigemasa, and M. Takagi. 2001. Gene expression and immunohistochemical localization of decorin and biglycan in association with early bone formation in the developing mandible. J. Oral Sci. 43: 179-188.
23. Corsi, A., T. Xu, X. D. Chen, A. Boyde, J. Liang, M. Mankani, B. Sommer, R. V. Iozzo, I. Eichstetter, P. G. Robey, et al. 2002. Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J. Bone Miner. Res. 17: 1180-1189. (Pubitemid 34680494)
24. Chen, X. D., S. Shi, T. Xu, P. G. Robey, and M. F. Young. 2002. Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells. J. Bone Miner. Res. 17: 331-340. (Pubitemid 34087666)
25. Douglas, T., S. Heinemann, U. Hempel, C. Mietrach, C. Knieb, S. Bierbaum, D. Scharnweber, and H. Worch. 2008. Characterization of collagen II fibrils containing biglycan and their effect as a coating on osteoblast adhesion and proliferation. J. Mater. Sci. Mater. Med. 19: 1653-1660. (Pubitemid 351409324)
26. Schaefer, L., D. Mihalik, A. Babelova, M. Krzyzankova, H. J. Gröne, R. V. Iozzo, M. F. Young, D. G. Seidler, G. Lin, D. P. Reinhardt, and R. M. Schaefer. 2004. Regulation of fibrillin-1 by biglycan and decorin is important for tissue preservation in the kidney during pressure-induced injury. Am. J. Pathol. 165: 383-396. (Pubitemid 38971370)
27. Leemans, J. C., L. M. Butter, W. P. Pulskens, G. J. Teske, N. Claessen, T. van der Poll, and S. Florquin. 2009. The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury. PLoS ONE 4: e5704.
28. Schaefer, L., K. F. Beck, I. Raslik, S. Walpen, D. Mihalik, M. Micegova, K. Macakova, E. Schonherr, D. G. Seidler, G. Varga, et al. 2003. Biglycan, a nitric oxide-regulated gene, affects adhesion, growth, and survival of mesangial cells. J. Biol. Chem. 278: 26227-26237. (Pubitemid 36835392)
29. Schaefer, L. 2010. Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr. Opin. Pharmacol. 10: 185-190.
30. Sousa, M. M., J. B. do Amaral, A. Guimarães, and M. J. Saraiva. 2005. Upregulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J. 19: 124-126. (Pubitemid 40069939)
31. Bereczki, E., S. Gonda, T. Csont, E. Korpos, A. Zvara, P. Ferdinandy, and M. Santha. 2007. Overexpression of biglycan in the heart of transgenic mice: an antibody microarray study. J. Proteome Res. 6: 854-861. (Pubitemid 46340189)
32. Ayada, Y., S. Kusachi, T. Murakami, S. Hirohata, S. Takemoto, I. Komatsubara, J. Hayashi, A. Iwabu, Y. Ninomiya, and T. Tsuji. 2001. Increased expression of biglycan mRNA in pressure-overloaded rat heart. Clin. Exp. Hypertens. 23: 633-643. (Pubitemid 33055283)
33. Ahmed, M. S., E. Øie, L. E. Vinge, A. Yndestad, G. Ø. Andersen G, Y. Andersson, T. Attramadal, and H. Attramadal. 2003. Induction of myocardial biglycan in heart failure in rats - an extracellular matrix component targeted by AT(1) receptor antagonism. Cardiovasc. Res. 60: 557-568. (Pubitemid 37501113)
34. Derbali, H., Y. Bossé, N. Côté, P. Pibarot, A. Audet, A. Pépin, B. Arsenault, C. Couture, J. P. Després, and P. Mathieu. 2010. Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2. Am. J. Pathol. 176: 2638-2645.
35. Westermann, D., J. Mersmann, A. Melchior, T. Freudenberger, C. Petrik, L. Schaefer, R. Lüllmann-Rauch, O. Lettau, C. Jacoby, J. Schrader, et al. 2008. Biglycan is required for adaptive remodeling after myocardial infarction. Circulation 117: 1269-1276. (Pubitemid 351365659)
36. Csont, T., and P. Ferdinandy. 2008. Letter by Csont and Ferdinandy regarding article, "Biglycan is required for adaptive remodeling after myocardial infarction". Circulation 118: e521; author reply e522.
37. Schaefer, L., A. Babelova, E. Kiss, H. J. Hausser, M. Baliova, M. Krzyzankova, G. Marsche, M. F. Young, D. Mihalik, M. Götte, et al. 2005. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 115: 2223-2233. (Pubitemid 41134165)
38. Babelova, A., K. Moreth, W. Tsalastra-Greul, J. Zeng-Brouwers, O. Eickelberg, M. F. Young, P. Bruckner, J. Pfeilschifter, R. M. Schaefer, H. J. Gröne, and L. Schaefer. 2009. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. Chem. 284: 24035-24048.
39. van Montfoort, N., M. G. Camps, S. Khan, D. V. Filippov, J. J. Weterings, J. M. Griffith, H. J. Geuze, T. van Hall, J. S. Verbeek, C. J. Melief, and F. Ossendorp. 2009. Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc. Natl. Acad. Sci. USA 106: 6730-6735.
40. Yewdell, J. W. 2007. Plumbing the sources of endogenous MHC class I peptide ligands. Curr. Opin. Immunol. 19: 79-86. (Pubitemid 46073699)
41. Chtanova, T., and C. R. Mackay. 2001. T cell effector subsets: extending the Th1/Th2 paradigm. Adv. Immunol. 78: 233-266. (Pubitemid 32566021)
42. Hochrein, H., K. Shortman, D. Vremec, B. Scott, P. Hertzog, and M. O'Keeffe. 2001. Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J. Immunol. 166: 5448-5455. (Pubitemid 32374165)
43. Maldonado-López, R., T. De Smedt, B. Pajak, C. Heirman, K. Thielemans, O. Leo, J. Urbain, C. R. Maliszewski, and M. Moser. 1999. Role of CD8alpha+ and CD8alpha- dendritic cells in the induction of primary immune responses in vivo. J. Leukoc. Biol. 66: 242-246. (Pubitemid 29379162)
44. O'Shea, J. J., and W. E. Paul. 2002. Regulation of T(H)1 differentiation - controlling the controllers. Nat. Immunol. 3: 506-508. (Pubitemid 34662299)
45. Parajuli, P., R. L. Mosley, V. Pisarev, J. Chavez, A. Ulrich, M. Varney, R. K. Singh, and J. E. Talmadge. 2001. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp. Hematol. 29: 1185-1193. (Pubitemid 32927219)
46. Paul, W. E., and R. A. Seder. 1994. Lymphocyte responses and cytokines. Cell 76: 241-251. (Pubitemid 24046687)
47. Burgdorf, S., A. Kautz, V. Böhnert, P. A. Knolle, and C. Kurts. 2007. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316: 612-616. (Pubitemid 46683149)
48. Dudziak, D., A. O. Kamphorst, G. F. Heidkamp, V. R. Buchholz, C. Trumpfheller, S. Yamazaki, C. Cheong, K. Liu, H. W. Lee, C. G. Park, et al. 2007. Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-111. (Pubitemid 46196991)
49. Carbone, F. R., C. Kurts, S. R. Bennett, J. F. Miller, and W. R. Heath. 1998. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol. Today 19: 368-373.
50. Bevan, M. J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143: 1283-1288.
51. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801. (Pubitemid 43261452)
52. Brown, G. D. 2008. Sensing necrosis with Mincle. Nat. Immunol. 9: 1099-1100.
53. Yamasaki, S., E. Ishikawa, M. Sakuma, H. Hara, K. Ogata, and T. Saito. 2008. Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nat. Immunol. 9: 1179-1188.
54. Zhou, R., A. Tardivel, B. Thorens, I. Choi, and J. Tschopp. 2010. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11: 136-140.
55. Cambi, A., and C. Figdor. 2009. Necrosis: C-type lectins sense cell death. Curr. Biol. 19: R375-R378.
56. Karttunen, J., S. Sanderson, and N. Shastri. 1992. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci. USA 89: 6020-6024.
57. Kresse, H., D. G. Seidler, M. Muller, E. Breuer, H. Hausser, P. J. Roughley, and E. Schonherr. 2001. Different usage of the glycosaminoglycan attachment sites of biglycan. J. Biol. Chem. 276: 13411-13416.
58. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rössner, F. Koch, N. Romani, and G. Schuler. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223: 77-92. (Pubitemid 29096240)
59. Villadangos, J. A., M. Cardoso, R. J. Steptoe, D. van Berkel, J. Pooley, F. R. Carbone, and K. Shortman. 2001. MHC class II expression is regulated in dendritic cells independently of invariant chain degradation. Immunity 14: 739-749. (Pubitemid 32592421)
60. Afanasyeva, M., Y. Wang, Z. Kaya, S. Park, M. J. Zilliox, B. H. Schofield, S. L. Hill, and N. R. Rose. 2001. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am. J. Pathol. 159: 193-203. (Pubitemid 33704204)
61. Göser, S., M. Andrassy, S. J. Buss, F. Leuschner, C. H. Volz, R. Ottl, S. Zittrich, N. Blaudeck, S. E. Hardt, G. Pfitzer, et al. 2006. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 114: 1693-1702. (Pubitemid 44607117)
62. Kaya, Z., S. Göser, S. J. Buss, F. Leuschner, R. Ottl, J. Li, M. Völkers, S. Zittrich, G. Pfitzer, N. R. Rose, and H. A. Katus. 2008. Identification of cardiac troponin I sequence motifs leading to heart failure by induction of myocardial inflammation and fibrosis. Circulation 118: 2063-2072.
63. Adams, J., E. Kiss, A. B. Arroyo, M. Bonrouhi, Q. Sun, Z. Li, N. Gretz, A. Schnitger, C. C. Zouboulis, M. Wiesel, et al. 2005. 13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy. Am. J. Pathol. 167: 285-298. (Pubitemid 40884789)
64. Burgdorf, S., C. Schölz, A. Kautz, R. Tampé, and C. Kurts. 2008. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol. 9: 558-566. (Pubitemid 351560525)
65. Scott, M. J., and T. R. Billiar. 2008. Beta2-integrin-induced p38 MAPK activation is a key mediator in the CD14/TLR4/MD2-dependent uptake of lipopolysaccharide by hepatocytes. J. Biol. Chem. 283: 29433-29446.
66. Klotz, L., S. Hucke, D. Thimm, S. Classen, A. Gaarz, J. Schultze, F. Edenhofer, C. Kurts, T. Klockgether, A. Limmer, et al. 2009. Increased antigen cross-presentation but impaired cross-priming after activation of peroxisome proliferator-activated receptor gamma is mediated by up-regulation of B7H1. J. Immunol. 183: 129-136.
67. Eriksson, U., R. Ricci, L. Hunziker, M. O. Kurrer, G. Y. Oudit, T. H. Watts, I. Sonderegger, K. Bachmaier, M. Kopf, and J. M. Penninger. 2003. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat. Med. 9: 1484-1490. (Pubitemid 38004775)
68. Kolk, M. V., D. Meyberg, T. Deuse, K. R. Tang-Quan, R. C. Robbins, H. Reichenspurner, and S. Schrepfer. 2009. LAD-ligation: a murine model of myocardial infarction. J. Vis. Exp. Oct 14;(32). pii: 1438.
69. Schaefer, L., H. Hausser, M. Altenburger, J. Ugorcakova, C. August, L. W. Fisher, R. M. Schaefer, and H. Kresse. 1998. Decorin, biglycan and their endocytosis receptor in rat renal cortex. Kidney Int. 54: 1529-1541. (Pubitemid 28502895)
70. Yamamoto, K., S. Kusachi, Y. Ninomiya, M. Murakami, M. Doi, K. Takeda, T. Shinji, T. Higashi, N. Koide, and T. Tsuji. 1998. Increase in the expression of biglycan mRNA expression Co-localized closely with that of type I collagen mRNA in the infarct zone after experimentally-induced myocardial infarction in rats. J. Mol. Cell. Cardiol. 30: 1749-1756. (Pubitemid 28430188)
71. Dressler, W. 1959. Flare-up of pericarditis complicating myocardial infarction after two years of steroid therapy. Am. Heart J. 57: 501-506.
72. Dressler, W. 1959. The post-myocardial-infarction syndrome: a report on forty-four cases. AMA Arch. Intern. Med. 103: 28-42.
73. Haiat, R. 1981. Post-myocardial infarction constrictive pericarditis. Am. Heart J. 101: 358.
74. Indik, J. H., and J. S. Alpert. 2000. Post-Myocardial Infarction Pericarditis. Curr. Treat. Options Cardiovasc. Med. 2: 351-356.
75. Krainin, F. M., A. P. Flessas, and D. H. Spodick. 1984. Infarction-associated pericarditis. Rarity of diagnostic electrocardiogram. N. Engl. J. Med. 311: 1211-1214. (Pubitemid 14021924)
76. Spodick, D. H. 2004. Decreased recognition of the post-myocardial infarction (Dressler) syndrome in the postinfarct setting: does it masquerade as "idiopathic pericarditis" following silent infarcts? Chest 126: 1410-1411. (Pubitemid 39525009)
77. Stubbs, D. F. 1986. Post-acute myocardial infarction symptomatic pericarditis (PAMISP): report on a large series and the effect of methylprednisolone therapy. J. Int. Med. Res. 14(Suppl. 1): 25-29. (Pubitemid 16073704)
78. Turk, M. 1989. Acute pericarditis in the post-myocardial infarction patient. Crit. Care Nurs. Q. 12: 34-38. (Pubitemid 20068141)
79. Shen, L., and K. L. Rock. 2006. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr. Opin. Immunol. 18: 85-91. (Pubitemid 43049653)
80. Melief, C. J. 2003. Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol. 33: 2645-2654. (Pubitemid 37337130)
81. Bevan, M. J. 2006. Cross-priming. Nat. Immunol. 7: 363-365.
82. Mukhopadhaya, A., T. Hanafusa, I. Jarchum, Y. G. Chen, Y. Iwai, D. V. Serreze, R. M. Steinman, K. V. Tarbell, and T. P. DiLorenzo. 2008. Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc. Natl. Acad. Sci. USA 105: 6374-6379. (Pubitemid 351758353)
83. Villadangos, J. A., and W. R. Heath. 2005. Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. Semin. Immunol. 17: 262-272. (Pubitemid 40981932)
84. Barton, G. M., and J. C. Kagan. 2009. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat. Rev. Immunol. 9: 535-542.
85. Köllisch, G., B. N. Kalali, V. Voelcker, R. Wallich, H. Behrendt, J. Ring, S. Bauer, T. Jakob, M. Mempel, and M. Ollert. 2005. Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 114: 531-541. (Pubitemid 40478147)
86. Lee, H. K., S. Dunzendorfer, and P. S. Tobias. 2004. Cytoplasmic domain-mediated dimerizations of toll-like receptor 4 observed by beta-lactamase enzyme fragment complementation. J. Biol. Chem. 279: 10564-10574. (Pubitemid 38372668)
87. Lorenz, E. 2006. TLR2 and TLR4 expression during bacterial infections. Curr. Pharm. Des. 12: 4185-4193. (Pubitemid 44669747)
88. Laflamme, N., H. Echchannaoui, R. Landmann, and S. Rivest. 2003. Cooperation between toll-like receptor 2 and 4 in the brain of mice challenged with cell wall components derived from gram-negative and gram-positive bacteria. Eur. J. Immunol. 33: 1127-1138. (Pubitemid 36546701)
89. Zhou, Q., T. Desta, M. Fenton, D. T. Graves, and S. Amar. 2005. Cytokine profiling of macrophages exposed to Porphyromonas gingivalis, its lipopolysaccharide, or its FimA protein. Infect. Immun. 73: 935-943. (Pubitemid 40165752)
90. Pummerer, C. L., K. Luze, G. Grässl, K. Bachmaier, F. Offner, S. K. Burrell, D. M. Lenz, T. J. Zamborelli, J. M. Penninger, and N. Neu. 1996. Identification of cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice. J. Clin. Invest. 97: 2057-2062.
91. Hayward, S. L., N. Bautista-Lopez, K. Suzuki, A. Atrazhev, P. Dickie, and J. F. Elliott. 2006. CD4 T cells play major effector role and CD8 T cells initiating role in spontaneous autoimmune myocarditis of HLA-DQ8 transgenic IAb knockout nonobese diabetic mice. J. Immunol. 176: 7715-7725. (Pubitemid 43849072)
92. Berard, J. L., K. Wolak, S. Fournier, and S. David. 2010. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 58: 434-445.
93. Friese, M. A., and L. Fugger. 2009. Pathogenic CD8(+) T cells in multiple sclerosis. Ann. Neurol. 66: 132-141.
94. Latif, N., P. Sarathchandra, P. M. Taylor, J. Antoniw, and M. H. Yacoub. 2005. Localization and pattern of expression of extracellular matrix components in human heart valves. J. Heart Valve Dis. 14: 218-227. (Pubitemid 47046901)